pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

COMPANY OVERVIEW

IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.

LOCATION

  • Copenhagen, , Denmark

    • THERAPEUTIC AREAS

  • Immunology

  • Oncology

    • WEBSITE

    https://www.iobiotech.com/

    CAREER WEBSITE

    None

    SOCIAL MEDIA

    INVESTORS

    lundbeckfonden novo-holdings sunstone-capital

    PRESS RELEASES


    Nov 9, 2021

    Novo Holdings and Lundbeckfonden Portfolio Company IO Biotech Closes Initial Public Offering on the Nasdaq Global Market


    Sep 14, 2021

    IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial


    Jul 8, 2021

    IO Biotech Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer


    May 25, 2021

    IO Biotech Strengthens Leadership Team with Appointment of Dr. Muhammad Al-Hajj as Chief Scientific Officer


    Jan 13, 2021

    IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology


    For More Press Releases
    Google Analytics Alternative